276 LP attempts were examined prospectively by physician questionnaire and medical record review. Factors occurring at the time of LP as well as time required for CSF receipt at the laboratory (DEL) ...
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant ...
This story was updated on 18 April 2017 to correct an error. Cerebrospinal fluid biomarkers of Alzheimer’s disease have transformed clinical research, but ...
Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with ...
Director, Molecular Microbiology Assistant Director, Clinical Microbiology and Immunoserology Laboratories Nationwide Children's Hospital Associate Professor - Clinical, College of Medicine, The Ohio ...
Roche is on a roll: For the second time in less than a year, the company has scored FDA clearance for a pair of assays that can be used together to help spot signs of Alzheimer’s disease. The duo ...
In a recent study published in Jama Network, researchers investigated the impact of coronavirus disease 2019 (COVID-19) on biomarkers in the cerebrospinal fluid (CSF). Study: Viral Antigen and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results